NEW YORK, Nov. 25, 2014 (GLOBE NEWSWIRE) -- The Rosen Law Firm announces that a class action lawsuit has been filed on behalf of purchasers of Alcobra Ltd. common stock (Nasdaq:ADHD) during the period from March 28, 2014 through November 14, 2014. The class action seeks to recover investors' losses under the federal securities laws.
To join the Alcobra class action, go to the website http://www.rosenlegal.com/cases-448.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action.
The lawsuit asserts Alcobra misrepresented the results of its Phase 3 clinical trials for its product candidate MDX intended for treating attention deficit hyperactivity disorder. Specifically, the complaint alleges that Alcobra misled investors by misrepresenting or concealing that: (1) MDX did not show a statistical benefit over placebo except after it removed certain patients from the Phase 3 study analysis; (2) Alcobra presented its analyses inconsistently, including post hoc analysis outside the original protocols; and (3), as a result Alcobra's statements about the clinical success of MDX, were false and misleading and or lacked a reasonable basis.
The complaint alleges that as a result of Alcobra's misleading statements, its share price has declined, damaging investors.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 19, 2015. If you wish to join the class action go to http://www.rosenlegal.com/cases-448.html or to discuss your rights or interests regarding this class action, please contact, Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.